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Abstract—New hydroxy azepanes with an additional hydroxymethyl side arm have been conceived and their syntheses achieved
from a suitably functionalized cyclohexanoid building-block extracted from the norbornyl framework. The new iminocyclitols
(homoisofagomine derivatives) exhibit weak but selective inhibitory activity in enzyme assays. 
Replacement of ring oxygen with basic nitrogen in
sugars gives rise to azasugars (also referred to as imino
sugars) and these entities have not only been found in
Nature but also aroused a great deal of synthetic
interest in recent years because of their ability to inhibit
glycosidases.1 While deoxynojirimycin 1 constitutes a
well known example of a potent naturally occuring
glycosidase inhibitor, 1-deoxyfuconojirimycin 2 is a
synthetic analogue2a and the most powerful inhibitor of
-fucosidases known to date. This impressive biological
activity profile of iminosugars and their potential for
therapeutic applications has stimulated interest in the
synthesis of newer analogues through manipulation of
the number and stereochemical disposition of the
hydroxyl groups, relocation of the hydroxymethyl arm
as in the potent inhibitor isofagomine 3,2b,c,e introduc-
tion of additional ring nitrogen atom as in the diaza-
sugar 42d among others. More recently, iminocyclitols
based on seven-membered rings having the same car-
bon content as the azasugars but endowed with the
conformational advantage of a more flexible azepane
ring that could lead to favorable binding to the active
site of the enzyme have been introduced.3 Indeed, imi-
nocyclitols 5–7 have shown promising glycosidase inhi-
bition profiles. We have visualized another variant of
the seven-membered iminocyclitols with an additional
binding site in the form of a hydroxymethyl arm, which
can be regarded as a hybrid of the polyhydroxy-
azepanes and isofagomine 3. Syntheses of several of
these new iminocyclitols 8 form the subject matter of
this letter.
Recently, we have delineated a convenient access to a
functionalized cyclohexenoid 10 from a norbornyl pre-
cursor 9 involving a fragmentation protocol.4a It has
been shown that 10 is a versatile building block, com-
parable to the cyclohexadiene-diols derived through
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microbial hydroxylation of arenes,5 for the synthesis of
diverse cyclitols and related structures.4 Herein, we
further demonstrate the utility of 10 in the synthesis of
novel hydroxyazepanes related to 8 (Scheme 1). Elabo-
ration of 10 to azepanes required oxidative cleavage of
the cyclohexanoid ring to set-up either a double reduc-
tive amination or inter- and intramolecular N-alkyla-
tions to deliver system 8. Towards this end, 10 was
transformed to the cis-1,2-diol 116 via LiAlH4 reduc-
tion, protection of the resulting primary hydroxyl func-
tionality and stereoselective catalytic OsO4
dihydroxylation. Periodate mediated oxidative cleavage
to the dialdehyde, sodium borohydride reduction and
mesylation on 11 proceeded uneventfully to furnish the
dimesylate 12 (Scheme 1).6 Exposure of 12 to p-toluene-
sulfonamide under phase transfer conditions resulted in
smooth inter- and the intramolecular N-alkylations to
13. The N-tosyl group in 13 could be reductively
removed with sodium naphthalenide and the resulting
free amine was characterized as the acetamide 14,
which existed as a mixture of two rotamers. Deprotec-
tion maneuvers in 14 led to a homoisofagomine (carbon
inserted between nitrogen and hydroxymethyl group of
3) derivative 15 (Scheme 1).6 An isomeric
homoisofagomine derivative with a carbon inserted
between the hydroxymethyl group and the neighboring
hydroxy group was also prepared from 10 through a
tactically altered route. Cyclohexenoid 10 was first elab-
orated to 16 through LiAlH4 reduction, stereoselective
catalytic dihydroxylation and acetylation (Scheme 2).6
Acetonide deprotection in 16 gave 17 and the 1,2-diol
functionality was subjected to periodate cleavage to
Scheme 1. Reagents and conditions : (a) i. LAH, THF, 0–5°C, 1 h, 90%, ii. BnBr, NaH, THF, rt, 6 h, 95%, iii. OsO4, NMMO,
Me2CO–H2O (4:1), rt, overnight, 83%; (b) i. NaIO4–silica gel, DCM, 0°C, 2 h, ii. NaBH4, MeOH, 0°C, 1 h, iii. MsCl, Et3N,
DCM, 0°C, 1.5 h, 55% (three steps); (c) pTsNH2, KOH, TBAI, C6H6–H2O (9:1), reflux, 24 h, 60%; (d) i. Na-naphthalenide, DME,
−60°C, 1 h, ii. Ac2O, Py, rt, overnight, 67% (two steps); (e) i. H2, Pd/C, EtOH, 12 h, ii. 1N HCl, 90°C, 85% (two steps).
Scheme 2. Reagents and conditions : (a) i. LAH, THF, 0–5°C, 1 h, 90%, ii. OsO4, NMMO, Me2CO–H2O (4:1), rt, overnight, 82%,
iii. Ac2O, DMAP, DCM, rt, 10 h, 78%; (b) Amberlyst-15, THF–H2O (2:3), rt, 12 h, 85%; (c) NaIO4–silica gel, DCM, 0°C, 2 h;
(d) BnNH2, AcOH, NaCNBH3, MeOH, 12 h, 35% (two steps); (e) K2CO3, MeOH, rt, 6 h, 95%; (f) i. H2, Pd/C, EtOH, rt, 5 h,
ii. 1N HCl, 90°C, 24 h, 90%.
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Scheme 3. Reagents and conditions : (a) i. LAH, THF, 0–5°C, 3 h, 70%, ii. Ac2O, DMAP, DCM, rt, 12 h, 89%, iii. Amberlyst-15,
THF–H2O (2:3), rt, 12 h, 85%; (b) NaIO4–silica gel, DCM, 0°C, 2 h; (c) BnNH2, AcOH, NaCNBH3, MeOH, 15 h, 30% (two
steps); (d) K2CO3, MeOH, rt, 6 h, quant.; (e) i. H2, Pd/C, EtOH, rt, 5 h, ii. 1N HCl, 90°C, 20 h, 90%.
deliver the intermediate dialdehyde 18, which was
directly subjected to a double-reductive amination7 to
give the azepane 19 as the major product (Scheme 2).6
While acetate hydrolysis in 19 gave the N-benzyl-pro-
tected trihydroxy azepane 20, reductive removal of the
N-benzyl group and deprotection gave the trihydroxy
azepane 21 (Scheme 2).6
Another homoisofagomine related to 21 with a ‘skipped
hydroxyl’ pattern was accessed from the endo-nor-
bornyl derivative 22. Regioselective Baeyer–Villiger oxi-
dation of 22 gave 23 as the major product (87:13
mixture of regioisomers). A sequence consisting of
LiAlH4 reduction, per-acetylation and acetonide depro-
tection in 23 led to cyclohexane-1,2-diol 24 (Scheme 3).6
Periodate cleavage in 24 led to an intermediate dialde-
hyde 25, which was directly subjected to double-reduc-
tive amination with benzylamine to give the azepane
triacetate 26 as the major product. Acetate hydrolysis
in 26 gave the N-benzyl trihydroxy derivative 27. On
the other hand, reductive removal of the N-benzyl
group and acetate deprotection furnished the trihydroxy-
azepane 28 (Scheme 3).6
The new homoisofagomine analogues 15, 20, 21, 27 and
28 were assayed for glycosidase inhibition against a set
of six commonly used enzymes (- and -glucosidase,
- and -galactosidase, and - and -mannosidase)
following standard protocols. All the substrates exam-
ined exhibited weak but selective inhibition with 20 and
21 showing relatively better activity against -glucosi-
dase (Ki=470 M) and -galactosidase (Ki=600 M),
respectively. It is quite interesting that while the N-ben-
zyl derivative 20 shows inhibition of -glucosidase, the
unprotected 21 inhibits -galactosidase. This change in
enzyme selectivity in the case of 20 and 21 mediated
only by the protective group, without any alteration in
the disposition or stereochemistry of the hydroxyl
groups, is quite unusual and may have useful implica-
tions. We have observed similar selectivity in the case of
27 and 28, as well with the former exhibiting weak
inhibition of -glucosidase and the latter inhibiting
-glucosidase.8
In conclusion, we have amplified the synthetic utility of
the cyclohexenoid building block 10 by devising
stereoselective routes to new hydroxyazepanes with a
homoisofagomine framework. While the azepanes
reported here have only weak glycosidase inhibitory
activity compared to those reported earlier, our results
of enzymatic assays reveal the importance of N-substi-
tution in modulating selectivity and inhibition efficacy.
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